Is plasma amyloid- β 1–42/1–40 a better biomarker for Alzheimer’s disease than AβX–42/X–40?

ConclusionsOur findings support the hypothesis that the relatively small difference in the plasma A β42/40 ratio between subjects with and without evidence of brain amyloidosis can be accentuated by specifically measuring Aβ1–42/1–40 instead of AβX–42/X–40. A simplified theoretical model explaining this observation is presented.

http://link.springer.com/10.1186/s12987-022-00390-4

Source: Fluids and Barriers of the CNS - December 3, 2022 Category: Neuroscience Source Type: research